MHMohamed Abdel Fattah Hegazy

Mohamed Abdel Fattah Hegazy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Abdel Fattah Hegazy has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metastatic rhabdomyosarcoma of the thyroid gland, a case report

    by Mohamed T Hafez, Mohamed A Hegazy, Khaled Abd Elwahab, Mohammad Arafa, Islam Abdou, Basel Refky

    The thyroid gland is a known but an unusual site for metastatic tumors from various primary sites. Despite the fact that it is one of the largest vascular organs in the body, clinical and surgical cases have given an incidence of 3 % of secondary malignances of the organ. Nevertheless, thyroid metastases are not an exceptional finding at autopsy, they are encountered in 2 % to 24 % of the patients with malignant neoplasm.


  • Open Access

    Can we put a simplified algorithm for reconstruction of large scalp defects following tumor resection?

    by Adel Denewer, Ashraf Khater, Omar Farouk, Mohammad Hegazy, Mahmoud Mosbah, Mohammad Hafez, Fayez Shahatto, Sameh Roshdy, Waleed Elnahas, Mohammad Kasem

    Reconstruction of large scalp defects after tumor resection is a challenging problem. We aimed at putting an algorithm for reconstruction of those defects.


  • Surgical outcome of modified versus conventional parotidectomy in treatment of benign parotid tumors

    by Mohamed Abdel Fattah Hegazy, Waleed El Nahas, Sameh Roshdy

    Background: Our proposed modified technique includes creating a posterior pedicle parotid gland fascia flap without separating the great auricular nerve branches through an aesthetic incision. This fascial flap is sutured back to the parotid bed creating a barrier of the aberrant regeneration of sympathetic fibers thus, theoretically, decreasing the incidence of Frey's syndrome.Patients and methods: Superficial parotidectomy for benign parotid neoplasms was carried out using either the conventional (Group 1) or modified (Group 2) technique. Outcomes of the two groups were reviewed. Both techniques were compared for the cosmetic outcome, great auricular nerve anesthesia, and the incidence of Frey's syndrome.Results: The incision in the modified group was more cosmetic both subjectively and objectively. Postoperatively, transient numbness was reported by 21% of cases in the modified group. In the control group, transient sensory deficit was complained by all cases. Fourteen patients restored sensation completely within 2 years after surgery. The incidence of subjective Frey's syndrome was significantly lower in the modified group. Objectively, on starch iodine test, the incidence of Frey's syndrome was higher in both groups.Conclusion: In selected cases of benign parotid neoplasm, modified parotidectomy is an effective technique in improving the outcome of the procedure. J. Surg. Oncol. 2011; 103:163–168.


  • Minimally Invasive Video‐Assisted Thyroidectomy for Small Follicular Thyroid Nodules

    by Mohamed A. F. Hegazy, Ashraf A. Khater, Ahmed E. Setit, Mahmoud A. Amin, Sherif Z. Kotb, Mohamed A. El Shafei, Tamer F. Yousef, Osama Hussein, Yousef K. Shabana, Ola T. Abdel Dayem

    Minimal access surgery in the thyroid compartment has evolved considerably over the past 10 years and now takes many forms. This study examined the feasibility and reliability of minimally invasive thyroid surgery for the management of small benign thyroid lesions. A total of 68 patients with small thyroid nodules admitted to the Oncology Center of Mansoura University, Egypt, were enrolled in this prospective randomized trial. Patients were allotted to one of two procedures: minimally invasive video-assisted thyroidectomy (MIVAT) or minimally invasive open thyroidectomy using the Sofferman technique of strap muscle transection. Exclusion criteria were nodules > 4 cm, presence of thyroiditis, and thyroid gland volume > 20 ml. Preoperative diagnosis, operating time, blood loss, postoperative pain, complications, and cosmetic outcome were all evaluated. The MIVAT group included 35 patients, and the Sofferman group included 33 patients. The main preoperative pathology was a benign follicular lesion (70.5%), and the main postoperative final pathology was follicular adenoma (54.4%). The two groups were comparable regarding age, sex, and extent of thyroid surgery. Operating time was significantly longer in the MIVAT group (115.4 ± 33.5 minutes) compared to the Sofferman group (65.6 ± 23.7 minutes). The postoperative course was significantly less painful in the MIVAT group (p < 0.05). Although patients in the MIVAT group had smaller incisions (p < 0.05), the cosmetic outcome in the two groups was comparable. No long-term complication was encountered in either group. Two distinct approaches of minimally invasive thyroidectomy are now available and can be performed safely in selected patients. Despite some MIVAT advantages of less postoperative pain and slightly better cosmesis, minimally invasive open thyroidectomy offers an advantage of less operating time with comparable cosmetic results.


  • Preoperative Isolated Limb Infusion of Doxorubicin and External Irradiation for Limb-Threatening Soft Tissue Sarcomas

    by Mohamed A. F. Hegazy, Sherif Z. Kotb, Hanem Sakr, Ebrahim El Dosoky, Talal Amer, Refaat A. F. Hegazi, Omar Farouk

    At present, limb-sparing surgery is the most appropriate and acceptable treatment option for soft tissue sarcomas of the extremities. To increase the number of limb-sparing resections in the treatment of locally advanced soft tissue sarcomas of the extremities, preoperative radiotherapy and/or chemotherapy are often used. Isolated limb perfusion of cytostatic agents is an effective alternative option but technically complex. Isolated limb infusion, essentially a low-flow isolated limb perfusion without oxygenation via a percutaneous catheter, had been developed as a simple alternative. The objective of this study was to achieve limb-sparing surgery in patients with locally advanced soft tissue sarcomas of the extremities that would otherwise have required an amputation or a functionally mutilating surgery by performing preoperative isolated limb infusion with doxorubicin and external beam irradiation to obtain local control and make limb-sparing surgery feasible. A total of 40 patients with locally advanced soft tissue sarcomas of the extremities were evaluated between 2002 and 2005. Tumors were located in the lower limb in 28 patients (70%) and in the upper limb in 12 patients (30%). All of these patients were felt to be unresectable and were referred because amputation was considered the only available treatment option. They underwent preoperative isolated limb infusion with doxorubicin (0.7 and 1.4 mg/kg for the upper and lower limbs, respectively). Preoperative external beam radiotherapy started within 3–7 days after isolated limb infusion was administered. The total dose was 35 Gy in ten fractions. After 3–7 weeks, surgery was performed aiming at limb preservation. Tumor response was seen in 85% of patients, rendering these large sarcomas resectable in most cases. The mean values of pretreatment tumor volume and post-treatment volume were 2797 cm3 and 1781 cm3, respectively, with a significant p value of 0.0001. Histologic response was seen in 80% of patients. At a median followup of 15 months (range = 5–35), limb salvage was achieved in 82.5%. Procedure-related complications were limited and easily managed. Isolated limb infusion with doxorubicin is a simple and safe method of regional chemotherapy. The addition of preoperative external beam irradiation helped to increase the rate of limb salvage in patients with large and/or high-grade soft tissue sarcomas of the extremities.


  • Open Access

    Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma

    by Mohamed Af Hegazy, Refaat Af Hegazi, Mohamed A Elshafei, Ahmed E Setit, Maged R Elshamy, Mohamed Eltatoongy, Amal Af Halim

    Background: Patients with advanced ovarian cancer should be treated by radical debulking surgery aiming at complete tumor resection. Unfortunately about 70% of the patients present with advanced disease, when optimal debulking can not be obtained, and therefore these patients gain little benefit from surgery. Neoadjuvant chemotherapy (NACT) has been proposed as a novel therapeutic approach in such cases. In this study, we report our results with primary surgery or neoadjuvant chemotherapy as treatment modalities in the specific indication of operable patients with advanced ovarian carcinoma (no medical contraindication to debulking surgery). Patients and methods: A total of 59 patients with stage III or IV epithelial ovarian carcinomas were evaluated between 1998 and 2003. All patients were submitted to surgical exploration aiming to evaluate tumor resectability. Neoadjuvant chemotherapy was given (in 27 patients) where optimal cytoreduction was not feasible. Conversely primary debulking surgery was performed when we considered that optimal cytoreduction could be achieved by the standard surgery (32 patients). Results: Optimal cytoreduction was higher in the NACT group (72.2%) than the conventional group (62.4%), though not statistically significant (P = 0.5). More important was the finding that parameters of surgical aggressiveness (blood loss rates, ICU stay and total hospital stay) were significantly lower in NACT group than the conventional group. The median overall survival time was 28 months in the conventional group and 25 months in NACT group with a P value of 0.5. The median disease free survival was 19 months in the conventional group and 21 months in NACT group (P = 0.4). In multivariate analysis, the pathologic type and degree of debulking were found to affect the disease free survival significantly. Overall survival was not affected by any of the study parameters. Conclusion: Primary chemotherapy followed by interval debulking surgery in select group of patients doesn't appear to worsen the prognosis, but it permits a less aggressive surgery to be performed.